Evaluation of the Efficacy of Suprascapular Nerve Block in Adhesive Capsulitis

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorCHU de Reims

About this trial

This is a double-blind interventional superiority study evaluating the efficacy of suprascapular nerve block in addition to conventional therapies for adhesive capsulitis.

Adhesive capsulitis is a pathology that results in reduced shoulder mobility due to retraction of the periarticular capsule. It may be primary or secondary to traumatic or neurological events, or associated with diabetes in particular.

The usual treatment includes re-education sessions to improve joint amplitude and restore shoulder mobility. In persistent forms, intra-articular injection of cortisone is combined with distension of the capsule with a local anaesthetic under radiographic control.

In some countries, subscapular nerve block (reversible anaesthesia) is used to improve pain. The combination of arthrodistension and subscapular nerve block has never been performed to accelerate the healing process.

The aim of this study is to compare the performance of these two procedures together against the reference technique alone on time to improvement with the number of patients improved at one month according to the Constant score.

This score is used to assess shoulder pain and function, with a significant improvement above eight points.

Eligibility criteria

Qualifiers

Patient treated for adhesive capsulitis corresponding to a loss of passive amplitude of more than 20° in external rotation elbow to body and/or abduction in relation to the contralateral shoulder.

Patient over 18 years of age

Patient covered by a social security scheme

Presence of an accompanying person on the day of the procedure for the return trip

Disqualifiers

Patient protected by law

Pregnant women

Patient who has had shoulder surgery less than six months old

Patient unable to undergo rehabilitation within one month of surgery

Trial design

Treatments tested in this trial

  • Triamcinolone Acetonide
  • saline solution

Treatment groups

62 Participants
are divided into 2 treatment groups

Locations

1
Chu Reims51092, Reims France

Sponsors and collaborators

CHU de Reims

Lead sponsor